Beyond Air, Inc.

DB:48L Stock Report

Market Cap: €37.6m

Beyond Air Valuation

Is 48L undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 48L when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 48L's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 48L's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 48L?

Key metric: As 48L is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 48L. This is calculated by dividing 48L's market cap by their current revenue.
What is 48L's PS Ratio?
PS Ratio20.6x
SalesUS$2.34m
Market CapUS$39.41m

Price to Sales Ratio vs Peers

How does 48L's PS Ratio compare to its peers?

The above table shows the PS ratio for 48L vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.8x
AAQ1 aap Implantate
1.9xn/a€22.4m
GME Geratherm Medical
1x1.9%€21.0m
PUS PULSION Medical Systems
3.8xn/a€134.4m
AUG Audientes
12.6xn/a€6.9m
48L Beyond Air
20.6x89.2%€39.4m

Price-To-Sales vs Peers: 48L is expensive based on its Price-To-Sales Ratio (20.6x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 48L's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$830.14m
PHH2 Paul Hartmann
0.3xn/aUS$781.42m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
48L 20.6xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 48L is expensive based on its Price-To-Sales Ratio (20.6x) compared to the European Medical Equipment industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is 48L's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

48L PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.6x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: 48L is expensive based on its Price-To-Sales Ratio (20.6x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 48L forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.52
€2.35
+357.2%
60.0%€4.71€0.94n/a4
Nov ’25€0.45
€3.40
+662.8%
71.5%€7.26€0.91n/a4
Oct ’25€0.31
€3.40
+1,004.5%
71.5%€7.26€0.91n/a4
Sep ’25€0.36
€3.40
+839.8%
71.5%€7.26€0.91n/a4
Aug ’25€0.50
€4.78
+855.4%
39.0%€7.40€3.24n/a3
Jul ’25€0.47
€5.48
+1,076.4%
36.3%€7.46€3.27n/a4
Jun ’25€1.11
€11.80
+963.4%
42.2%€17.80€6.56n/a5
May ’25€0.99
€11.80
+1,092.3%
42.2%€17.80€6.56n/a5
Apr ’25€1.58
€12.14
+666.4%
38.6%€17.74€6.54n/a5
Mar ’25€1.87
€12.14
+550.6%
38.6%€17.74€6.54n/a5
Feb ’25€1.55
€11.99
+675.8%
38.6%€17.53€6.46n/a5
Jan ’25€1.86
€12.44
+567.5%
35.3%€17.37€6.40n/a5
Dec ’24€1.42
€11.49
+709.2%
40.2%€17.47€6.44n/a6
Nov ’24€2.19
€13.41
+512.5%
26.2%€17.99€9.47€0.456
Oct ’24€2.26
€13.24
+485.0%
26.2%€17.76€9.35€0.316
Sep ’24€2.76
€13.03
+371.7%
26.2%€17.47€9.20€0.366
Aug ’24€3.22
€13.46
+317.6%
22.5%€17.23€9.07€0.506
Jul ’24€4.14
€14.20
+242.7%
22.6%€17.41€9.16€0.476
Jun ’24€4.85
€16.79
+246.3%
16.9%€21.45€13.06€1.115
May ’24€5.16
€16.79
+225.4%
16.9%€21.45€13.06€0.995
Apr ’24€5.94
€16.79
+182.5%
16.9%€21.45€13.06€1.585
Mar ’24€5.67
€16.79
+196.1%
16.9%€21.45€13.06€1.875
Feb ’24€6.06
€18.05
+197.7%
17.0%€22.57€13.74€1.555
Jan ’24€5.95
€18.05
+203.4%
17.0%€22.57€13.74€1.865
Dec ’23€5.43
€18.05
+232.6%
17.0%€22.57€13.74€1.425
Nov ’23€6.81
€18.87
+177.2%
15.4%€23.34€15.22€2.195

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

7D

4.4%

1Y

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.9%

1Y

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

7D

1.5%

1Y

17.7%